TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Nine US lawmakers, led by Representative Yvette D. Clarke, have asked Revlon CEO Michelle Peluso to respond to an FDA warning about manufacturing and testing deficiencies at the company’s Oxford, North Carolina facility. The FDA cited gaps in testing talc for asbestos and in quality controls, and requested product testing, a risk assessment and a remediation plan. The lawmakers’ letter adds congressional scrutiny; the company’s response and the status of corrective actions are not specified in the available report.
Nine members of Congress have written to Revlon Group Holdings CEO Michelle Peluso seeking answers after the FDA cited testing and quality-control deficiencies at the company’s Oxford, North Carolina, manufacturing facility. The intervention focuses on the company’s production of over-the-counter products and the agency’s concerns about testing talc for asbestos and maintaining adequate product specifications and controls.
The letter was led by Representative Yvette D. Clarke, according to Global Cosmetics News, which cited Clarke’s office as its source. The lawmakers’ request follows an FDA warning letter issued in June. The available report does not give the congressional letter’s date or reproduce its full list of questions to Revlon.
The FDA said Revlon had not demonstrated that it adequately tested incoming talc for asbestos. The agency also identified deficiencies in specifications and quality controls, including controls covering microbiological standards for yeast and mould. These are findings described by the FDA in its warning; they do not, by themselves, establish that a particular finished product contained asbestos or harmful levels of microbes.
The agency requested that Revlon test affected talc or finished products, carry out a risk assessment and provide a remediation plan. The source report does not state whether the company has completed those steps, what products or batches may be affected, or whether the FDA has accepted any corrective actions. The lawmakers also expressed concern about possible exposure among Black women and girls, pointing to their substantial participation in the US beauty and personal care market.
Congress Questions Revlon’s Safety Controls
The letter brings congressional scrutiny to an FDA compliance matter and puts added attention on how Revlon verifies ingredients and manages manufacturing quality for over-the-counter products. FDA findings about testing procedures and quality systems matter because those controls are intended to identify risks before products reach consumers. The warning described in the source does not establish that consumers were harmed, but it raises questions about whether the company’s processes met the agency’s requirements.
The lawmakers’ focus on potential exposure among Black women and girls connects the manufacturing issue to concerns about who uses beauty and personal care products and who may be affected if a product risk is confirmed. That concern is part of the lawmakers’ rationale; the source material does not identify a specific exposed group, quantify exposure, or report a confirmed health effect.
For consumers and retailers, the practical questions are whether any products or batches require additional testing, whether corrective measures are in place, and whether the FDA considers Revlon’s response adequate. Those details are not available in the report, so the warning should not be read as proof that all Revlon products are unsafe.
As an affiliate, we earn on qualifying purchases.
FDA Warning Behind the Letter
The congressional request follows a June FDA warning letter concerning Revlon’s Oxford facility and its over-the-counter drug manufacturing. The agency’s cited issues included the company’s documentation of testing for asbestos in incoming talc, as well as specifications and microbiological quality controls related to yeast and mould.
The FDA asked the company to test affected talc or finished products, assess risks and set out a plan to address the problems. The source account does not provide the full warning letter, identify the products under review, or describe the facility’s subsequent inspection history. The reported development is the lawmakers’ request for answers in response to the agency’s findings, not a reported product recall or a final determination about consumer exposure.
“Revlon had not demonstrated adequate testing of incoming talc for asbestos.”
— The FDA, as summarized in Global Cosmetics News
Product Exposure and Revlon’s Response
The available account does not say which products or batches may be affected, whether testing has found asbestos or other contaminants, or whether any consumers were exposed or harmed. It also does not provide Revlon’s response to the congressional letter or the company’s progress on the FDA’s requested assessment and remediation plan.
The exact date and full text of the lawmakers’ letter are not included in the report. Nor does the source establish whether the FDA has taken further action since issuing its warning. The findings concern manufacturing and quality-control deficiencies; they should not be treated as confirmation that a specific product is contaminated.
Revlon’s Answers and FDA Follow-Up
The next reported step is for Revlon to answer the lawmakers and clarify what testing, risk assessment and corrective work it has undertaken in response to the FDA. The source material does not give a response deadline or say whether Revlon has submitted the requested information.
Further information from the company or the FDA could clarify which materials or products were reviewed, what the tests found and whether the agency considers the corrective plan sufficient. Until those details are available, the scope of any potential consumer exposure and the outcome of the regulatory review remain unresolved.
Key Questions
Why did members of Congress write to Revlon?
Nine lawmakers, led by Representative Yvette D. Clarke, sought answers after an FDA warning cited manufacturing, testing and quality-control deficiencies at Revlon’s Oxford, North Carolina, facility.
What did the FDA identify?
The agency said Revlon had not demonstrated adequate testing of incoming talc for asbestos and cited deficiencies in specifications and quality controls, including microbiological standards for yeast and mould.
Did the FDA confirm that Revlon products contained asbestos?
No such confirmation appears in the available report. It describes a failure to demonstrate adequate testing and says the FDA requested testing of affected talc or finished products. It does not report test results or identify a contaminated product.
What did the FDA ask Revlon to do?
The agency requested testing of affected talc or finished products, a risk assessment and a remediation plan. The source does not state whether Revlon has completed these steps.
Has Revlon responded to the lawmakers?
The source material does not report a response from Revlon CEO Michelle Peluso or provide a deadline for one. The company’s position and the status of its corrective actions remain unclear.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
